1. BCL-2 levels do not predict azathioprine treatment response in inflammatory bowel disease, but inhibition induces lymphocyte apoptosis and ameliorates colitis in mice. (21st September 2018) Authors: Weder, B; Mozaffari, M; Biedermann, L; Mamie, C; Moncsek, A; Wang, L; Clarke, S H; Rogler, G; McRae, B L; Graff, C L; Ruiz, P A; Hausmann, M Journal: Clinical and experimental immunology Issue: Volume 193:Number 3(2018:Sep.) Page Start: 346 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DOP001 Effectiveness and safety of vedolizumab in anti-TNF naïve patients with inflammatory bowel disease: a multicentre retrospective European Crohn's and Colitis Organisation study. (16th January 2018) Authors: Kopylov, U; Verstockt, B; Biedermann, L; Sebastian, S; Pugliese, D; Sonnenberg, E; Steinhagen, P R; Arebi, N; Ron, Y; Kucharzik, T; Roblin, X; Ungar, B; Bar-Gil Shitrit, A; Ardizzone, S; Molander, P; Coletta, M; Peyrin-Biroulet, L; Bossuyt, P; Avni-Biron, I; Tsoukal, E I Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S029 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. DOP021 Immunosuppressive and anti-TNF treatment is associated with a lower risk of migration from B1-to-B3-stage in Crohn's disease: 10-year follow-up data from the Swiss IBD cohort study. (16th January 2018) Authors: Cernoch, P; Fournier, N; Scharl, M; Zeitz, J; Morell, B; Greuter, T; Schreiner, P; Misselwitz, B; Safroneeva, E; Schoepfer, A; Vavricka, S R; Rogler, G; Biedermann, L Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S044 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. OP037 Risk of cancer in inflammatory bowel disease patients is associated with age and recent use of immunomodulators, while biologics and aminosalicylates are protective factors: a cross-sectional and follow-up analysis of the Swiss IBD cohort study. (16th January 2018) Authors: Greuther, T; Scharl, S; Barthel, C; Rossel, J -B; Biedermann, L; Misselwitz, B; Vavricka, S; Rogler, G; Scharl, M Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S026 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. OP06 Gut–brain axis revisited: Shedding light on the mucosa-associated microbial composition in IBD patients with psychological distress, anxiety, and depression. (25th January 2019) Authors: Humbel, F; Juillerat, P; Scharl, M; Misselwitz, B; Schreiner, P; Macpherson, A; Rogler, G; von Känel, R; Yilmaz, B; Biedermann, L Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S003 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P181 IBD patients with early clinical and sonographic improvements achieve better long-term outcomes than patients with clinical improvements alone – one-year interim results of the TRUST BEYOND study. (21st January 2022) Authors: Kucharzik, T; Helwig, U; Seibold, F; Biedermann, L; Högenauer, C; Fischer, I; Kolterer, S; Rath, S; Hammer, L; Maaser, C Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i247 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P192 Extreme body mass indices are frequent in inflammatory bowel disease patients and are associated with higher disease activity in Crohn`s disease, but not in ulcerative colitis: a cross-sectional analysis of the Swiss IBD cohort study. (16th January 2018) Authors: Greuter, T; Porchet, F; Fournier, N; Biedermann, L; Schreiner, P; Scharl, M; Schoepfer, A; Safroneeva, E; Straumann, A; Rogler, G; Vavricka, S Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S195 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P279 Potential of managed care programmes for patients with inflammatory bowel diseases – results from a large survey study among physicians and IBD-patients in Germany, Austria and Switzerland (the EASEIBD study). (27th May 2021) Authors: Bokemeyer, B; Kaiser, C; Primas, C; Novacek, G; Biedermann, L; Seibold, F; Tappe, U; Bettenworth, D; Graw, J; Hartmann, P; Plachta-Danielzik, S; Schultz, C Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S310 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P286 Sustained improvement in health-related quality of life outcomes in patients with Ulcerative Colitis with long-term tofacitinib treatment in the open-label extension study, OCTAVE Open. (21st January 2022) Authors: Biedermann, L; Dubinsky, M C; Vermeire, S; Fellmann, M; Gardiner, S; Hur, P; Mundayat, R; Panés, J; Rubin, D T Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i317 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P350 Real-world data regarding treatment of ulcerative colitis patients with golimumab in Switzerland. (25th January 2019) Authors: Perrig, K; Rossel, J-B; Biedermann, L; Schreiner, P; Roth, R; Zeitz, J; Greuter, T; Vavricka, S; Krupka, N; Juillerat, P; Rogler, G; Misselwitz, B Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S278 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗